MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$14,744K
Free Cash flow
-$33,402K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from draw down of debt
Accrued expenses and other curre...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Selling and marketing expense (e...
Repayment of debt
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
218,375
191,203
195,999
442,497
Cost of revenue (excluding amortization and depreciation)
13,564
14,725
12,329
35,149
Research and development expense (reversal) recognized-Solriamfetol
-
-
-
32,094
Research and development expense recognized-Solriamfetol
13,397
11,231
42,106
-
Research and development expense (reversal) recognized-AXS-05
-
-
-
42,896
Research and development expense recognized-AXS-05
11,491
10,904
55,312
-
Research and development expense (reversal) recognized-AXS-07
-
-
-
15,379
Research and development expense recognized-AXS-07
4,584
5,470
21,421
-
Research and development expense (reversal) recognized-AXS-12
-
-
-
6,019
Research and development expense recognized-AXS-12
2,399
1,488
8,482
-
Research and development expense (reversal) recognized-AXS-14
-
-
-
5,951
Research and development expense recognized-AXS-14
3,544
2,696
8,485
-
Other research and development
3,073
13,985
8,703
11,942
General and administrative expense (excluding share-based compensation expense)
24,615
22,024
18,650
44,623
Selling and marketing expense (excluding stock-based compensation expense)
164,113
146,437
134,538
305,864
Stock-based compensation expense
27,148
23,438
22,730
23,103
Gain in fair value of contingent consideration
-1,496
590
-9,068
13,185
Interest expense, net
-1,540
-1,185
-1,172
-5,385
Other segment items
1,717
1,572
2,037
14,193
Segment net loss
-51,314
-64,542
-28,559
-47,229
Adjustments and reconciling items
0
0
0
0
Net loss
-51,314
-64,542
-28,559
-47,229
Stock-based compensation expense
27,148
23,438
22,730
23,103
Amortization of intangible asset
1,589
1,572
1,607
1,607
Amortization of debt discount
164
159
161
158
Loss on debt extinguishment
-
-
0
0
Depreciation
143
116
114
120
Gain in fair value of contingent consideration
-1,496
590
-9,068
13,185
Gain from lease modification
-
-
0
0
Non-cash lease expense
857
844
797
817
Right-of-use asset amortization for finance lease
1,155
679
553
684
Change in operating lease liability
-
-
-
-182
Accounts receivable, net
26,397
26,598
27,957
-2,318
Inventories, net
5,890
3,110
3,640
4,994
Prepaid expenses and other current assets
-2,146
9,872
-6,138
3,451
Non-current inventory and other assets
-855
1,762
-149
1,936
Accounts payable
-27,733
41,165
11,310
-37,401
Accrued expenses and other current liabilities
46,610
17,229
7,174
54,247
Operating lease liability
-789
-608
-535
-
Net cash used in operating activities
-32,952
-20,700
-18,653
1,046
Purchases of equipment
450
121
71
58
Net cash used in investing activities
-450
-121
-71
-58
Proceeds from draw down of debt
70,000
70,000
70,000
70,000
Payment of debt issuance costs
-
-
0
0
Repayment of debt
70,000
70,000
70,000
70,000
Payments on principal portion of finance lease obligation
1,210
672
541
664
Proceeds from issuance of common stock upon financing
13,474
6,343
5,675
9,946
Cash paid for common stock issuance costs
202
95
98
189
Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan
41,968
9,981
15,338
15,524
Payment of contingent consideration
-3,050
-3,262
-2,945
-2,507
Payments of tax withholdings on stock awards
2,834
9,301
1,044
842
Net cash provided by financing activities
48,146
2,994
16,385
21,268
Net decrease in cash
14,744
-17,827
-2,339
22,256
Cash at beginning of period
305,106
322,933
325,272
315,353
Cash at end of period
319,850
305,106
322,933
325,272
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from draw down of
debt
$70,000K
(-63.16%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$41,968K
(46.25%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$13,474K
(-74.23%↓ Y/Y)
Net cash provided by
financing activities
$48,146K
(-24.55%↓ Y/Y)
Canceled cashflow
$77,296K
Net decrease in cash
$14,744K
(219.51%↑ Y/Y)
Canceled cashflow
$33,402K
Repayment of debt
$70,000K
(-63.54%↓ Y/Y)
Payment of contingent
consideration
-$3,050K
(32.04%↑ Y/Y)
Payments of tax
withholdings on stock awards
$2,834K
(-45.75%↓ Y/Y)
Payments on principal
portion of finance lease...
$1,210K
(31.66%↑ Y/Y)
Cash paid for common
stock issuance costs
$202K
(-77.80%↓ Y/Y)
Accrued expenses and
other current...
$46,610K
(108.81%↑ Y/Y)
Stock-based compensation
expense
$27,148K
(-43.35%↓ Y/Y)
Prepaid expenses and
other current assets
-$2,146K
(-149.22%↓ Y/Y)
Amortization of intangible
asset
$1,589K
(-49.73%↓ Y/Y)
Right-of-use asset
amortization for finance...
$1,155K
(21.71%↑ Y/Y)
Non-cash lease expense
$857K
(-40.15%↓ Y/Y)
Non-current inventory and
other assets
-$855K
(-126.53%↓ Y/Y)
Amortization of debt discount
$164K
(-83.33%↓ Y/Y)
Depreciation
$143K
(-46.84%↓ Y/Y)
Net cash used in
operating activities
-$32,952K
(56.53%↑ Y/Y)
Net cash used in
investing activities
-$450K
(-28.21%↓ Y/Y)
Canceled cashflow
$80,667K
Net loss
-$51,314K
(52.22%↑ Y/Y)
Purchases of equipment
$450K
(28.21%↑ Y/Y)
Accounts payable
-$27,733K
(-241.27%↓ Y/Y)
Accounts receivable, net
$26,397K
(-53.55%↓ Y/Y)
Inventories, net
$5,890K
(190.72%↑ Y/Y)
Gain in fair value of
contingent consideration
-$1,496K
(77.30%↑ Y/Y)
Operating lease liability
-$789K
Revenue
$218,375K
Gain in fair value of
contingent consideration
-$1,496K
(77.30%↑ Y/Y)
Segment net loss
-$51,314K
(52.22%↑ Y/Y)
Canceled cashflow
$219,871K
Selling and marketing
expense (excluding...
$164,113K
Stock-based compensation
expense
$27,148K
(-43.35%↓ Y/Y)
General and
administrative expense...
$24,615K
Cost of revenue
(excluding amortization...
$13,564K
Research and development
expense...
$13,397K
Research and development
expense...
$11,491K
Research and development
expense...
$4,584K
Research and development
expense...
$3,544K
Other research and
development
$3,073K
Research and development
expense...
$2,399K
Other segment items
$1,717K
Interest expense, net
-$1,540K
Buy us a coffee
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)